Milestone Asset Management LLC Acquires Shares of 4,774 Axon Enterprise, Inc $AXON

Milestone Asset Management LLC acquired a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) in the second quarter, Holdings Channel reports. The firm acquired 4,774 shares of the biotechnology company’s stock, valued at approximately $3,953,000.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Axon Enterprise by 2.2% in the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after acquiring an additional 185,571 shares during the period. Alliancebernstein L.P. lifted its position in shares of Axon Enterprise by 15.9% in the first quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock worth $675,812,000 after buying an additional 175,890 shares in the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after buying an additional 212,931 shares in the last quarter. Northern Trust Corp raised its position in Axon Enterprise by 1.2% during the first quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock valued at $381,692,000 after purchasing an additional 8,794 shares during the period. Finally, Jennison Associates LLC raised its position in Axon Enterprise by 23,203.7% during the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock valued at $322,961,000 after purchasing an additional 611,418 shares during the period. Institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AXON. JMP Securities restated a “market outperform” rating and set a $825.00 price objective on shares of Axon Enterprise in a research report on Monday, September 29th. Wolfe Research began coverage on Axon Enterprise in a research note on Monday, July 7th. They issued an “outperform” rating on the stock. Zacks Research cut Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 2nd. Raymond James Financial reissued an “outperform” rating and issued a $855.00 price objective (up previously from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Axon Enterprise in a research note on Wednesday, October 8th. Fourteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $841.64.

Axon Enterprise Stock Down 1.1%

Shares of NASDAQ AXON opened at $724.10 on Tuesday. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $56.84 billion, a PE ratio of 178.79, a price-to-earnings-growth ratio of 29.49 and a beta of 1.41. The stock’s fifty day simple moving average is $730.27 and its two-hundred day simple moving average is $735.04. Axon Enterprise, Inc has a 12-month low of $424.99 and a 12-month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. During the same quarter in the prior year, the business posted $1.20 EPS. The business’s revenue for the quarter was up 32.6% compared to the same quarter last year. As a group, analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Brittany Bagley sold 5,000 shares of the firm’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $713.88, for a total value of $3,569,400.00. Following the completion of the transaction, the chief financial officer owned 93,592 shares in the company, valued at $66,813,456.96. This trade represents a 5.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $831.29, for a total value of $8,312,900.00. Following the completion of the transaction, the chief executive officer owned 3,053,982 shares of the company’s stock, valued at $2,538,744,696.78. This trade represents a 0.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 59,932 shares of company stock worth $45,115,616 over the last three months. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.